Get the Stockscreener App
0.2804
0.14%
0.0004
Pre-market:
.28
-0.0004
-0.14%
IGC Pharma Inc stock is traded at $0.2804, with a volume of 677.99K.
It is up +0.14% in the last 24 hours and down -1.96% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.28
Open:
$0.285
24h Volume:
677.99K
Relative Volume:
0.59
Market Cap:
$28.07M
Revenue:
$1.27M
Net Income/Loss:
$-7.12M
P/E Ratio:
-5.3716
EPS:
-0.0522
Net Cash Flow:
$-5.28M
1W Performance:
-6.22%
1M Performance:
-1.96%
6M Performance:
-16.05%
1Y Performance:
-6.53%
1-Day Range:
$0.2804
$0.2919
1-Week Range:
$0.28
$0.30
52-Week Range:
$0.242
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2804 | 28.07M | 1.27M | -7.12M | -5.28M | -0.0522 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
IGC Pharma Inc Stock (IGC) Latest News
IGC Reaches Enrollment Milestone in Alzheimer's Dementia Trial - GuruFocus
IGC Pharma (NYSE American: IGC) Alzheimer's Drug Gains Attention After Ascendiant Capital Raises Price Target - openPR.com
IGC Pharma (IGC) Inches Up 1.78% as It Approaches Key ResistanceSwing Entry Signals - newsline.com
Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight - 富途牛牛
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis - The Daily Corinthian
Alzheimer's agitation drug study nears final data as IGC enrolls 146 patients - Stock Titan
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts - BioSpace
IGC Maintained by Ascendiant Capital -- Price Target Raised to $5.50 - GuruFocus
IGC Pharma Extends and Amends $12 Million Loan Facility - TipRanks
IGC Pharma Extends $12 Million O-Bank Credit Facility; Increases Fee to $60,000 - TradingView
IGC Pharma (NYSE: IGC) extends $12M O-Bank loan facility with higher fee - Stock Titan
IGC Pharma, Inc. Enters Into Amendment To Extend Master Loan And Security Agreement With O-Bank Co., Ltd - marketscreener.com
Listed NanoCaps: PMI, IGC, WTC, WOK, SELX Radar Stocks to Watch Now! - openPR.com
Stocks to Watch: ANY, CMND, PRFX, OLOX, IGC Data Centers, AI, Quantum & Healthcare - FinancialContent
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis - Black Hills Pioneer
IGC Technical Analysis | Trend, Signals & Chart Patterns | IGC PHARMA INC (NYSEARCA:IGC) - ChartMill
IGC Stock Price, Quote & Chart | IGC PHARMA INC (NYSEARCA:IGC) - ChartMill
IGC Pharma Expands CALMA Trial with New Site at Mount Sinai - GuruFocus
IGC Pharma Adds Mount Sinai as CALMA Trial Nears Readout - ACCESS Newswire
IGC Pharma's (NYSE: IGC) CEO Appears on Bloomberg TV Discussing - openPR.com
IGC Pharma’s (NYSE: IGC) CEO Appears on Bloomberg TV Discussing Alzheimer’s Fast-Acting IGC-AD1 Pharmaceutical Therapeutic – More Stocks Inside - Barchart.com
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - Newswire.com
IGC Pharma Holds Steady at $0.29 as Stock Consolidates Near Key LevelsMoney Flow - The Legal Advocate
IGC Q1 2026 Earnings: Narrowing Losses on Lower Expenses as EPS Surprises to the UpsideEarnings Volatility Report - newsline.com
Alzheimer's AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in FocusMore Stocks Inside - openPR.com
Alzheimer’s AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in Focus – More Stocks Inside - Carroll County Mirror-Democrat
Daily Penny AlertsAlzheimer’s AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in Focus – More Stocks Inside - FinancialContent
IGC Pharma (IGC) Hovers Near Support After Modest Gain, Awaiting BreakoutETF NAV Deviation - newsline.com
IGC Q1 2026 Earnings: EPS Surpasses Estimates by 14.16% Amid Revenue ChallengesEarnings Revision Report - The Legal Advocate
IGC Pharma Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Edge LowerTrading Community - Newser
IGC Q1 2026 Earnings: Narrowing Losses as Cost Discipline Drives EPS BeatEarnings Power Value - newsline.com
IGC Pharma earnings beat, revenue topped estimates By Investing.com - Investing.com Australia
IGC Pharma (IGC) Q1 2026 Earnings: $-0.02 EPS Surges Past $-0.02 EstimatesEstimate Revision Count - Newser
IGC Pharma (IGC) Delivers Q1 2026 Beat — EPS $-0.02 vs $-0.02 ExpectedForward EPS Estimate - Newser
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment - BioSpace
IGC Pharma (IGC) Q1 2026 Earnings Surprise: EPS $-0.02, Up SignificantPopular Trader Picks - Newser
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference - Black Hills Pioneer
IGC Pharma, Inc. Common Stock (NY: IGC - The Chronicle-Journal
IGC Pharma (NYSE: IGC) deepens Alzheimer’s R&D amid tight cash and new loans - Stock Titan
IGC Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
IGC Unveils Tau-PET Biomarker Study for Alzheimer's at Global Ta - GuruFocus
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):